Tehran University of Medical Sciences

Science Communicator Platform

Share By
Genetically Modified Immune Cells Targeting Tumor Antigens Publisher Pubmed



Poorebrahim M1 ; Abazari MF2 ; Sadeghi S3 ; Mahmoudi R4 ; Kheirollahi A5 ; Askari H6 ; Wickstrom SL1 ; Poortahmasebi V7, 8, 9 ; Lundqvist A1 ; Kiessling R1 ; Cidarregui A10
Authors

Source: Pharmacology and Therapeutics Published:2020


Abstract

Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such ‘living’ therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy. © 2020 Elsevier Inc.
1. New Approaches in Cancer Immunotherapy: Review Article, Tehran University Medical Journal (2018)
3. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
Experts (# of related papers)
Other Related Docs
9. Gene Therapy and Genetic Vaccines, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
13. Immunotherapeutic Approaches for Cancer Therapy: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
17. Tumor Immunology, Clinical Immunology (2022)
18. Cell-Based Vaccines: Frontiers in Medical Technology for Cancer Treatment, Regenerative Engineering and Translational Medicine (2024)
19. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)